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RESEARCH ARTICLE
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Abstract
Mitochondrial dysfunction plays a significant role in neurodegenerative disease including
ataxias and other movement disorders, particularly those marked by progressive degenera-
tion in the cerebellum. In this study, we investigate the role of mitochondrial oxidative phos-
phorylation (OXPHOS) deficits in cerebellar tissue of a Purkinje cell-driven spinocerebellar
ataxia type 1 (SCA1) mouse. Using RNA sequencing transcriptomics, OXPHOS complex
assembly analysis and oxygen consumption assays, we report that in the presence of mutant
polyglutamine-expanded ataxin-1, SCA1 mice display deficits in cerebellar OXPHOS com-
plex I (NADH-coenzyme Q oxidoreductase). Complex I genes are upregulated at the time
of symptom onset and upregulation persists into late stage disease; yet, functional assembly
of complex I macromolecules are diminished and oxygen respiration through complex I is
reduced. Acute treatment of postsymptomatic SCA1 mice with succinic acid, a complex II
(succinate dehydrogenase) electron donor to bypass complex I dysfunction, ameliorated cer-
ebellar OXPHOS dysfunction, reduced cerebellar pathology and improved motor behavior.
Thus, exploration of mitochondrial dysfunction and its role in neurodegenerative ataxias, and
warrants further investigation.
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Introduction
Spinocerebellar ataxia type 1 (SCA1) is a progressive, autosomal dominant neurodegenerative
disease caused by a CAG repeat expansion in the ataxin-1 (ATXN1, SCA1) gene that produces
a polyglutamine expansion in the coded protein. Pathogenic alleles house 39–82 glutamine
and glutamine tract-length indirectly correlates with age of onset [1] likely due to strengthened
stability [2–4] of expanded ATXN1 protein and altered function in its role as a regulator of
gene expression and transcript splicing [5–7](reviewed in [2]). The primary site of SCA1 path-
ogenesis are cerebellar Purkinje neurons, the sole known cell type in which ATXN1 expression
is both cytoplasmic and nuclear [8–11].
With their extensively branched dendritic arbors and long axons, Purkinje neurons require
high metabolic activity [12, 13]. Mitochondrial generated ATP via oxidative phosphorylation
(OXPHOS) is essential for synaptic trafficking of specialized proteins and vesicles to proximal
and far distal regions as well as replenishment of the resting membrane potential via ion
pumps, among many other functions [13]. Reliance of Purkinje neurons on OXPHOS activity
is apparent in disorders of global mitochondrial dysfunction [14–18] and OXPHOS complex-
associated disorders [14, 19], in which Purkinje neurons are critically vulnerable.
OXPHOS complex dysfunction has been reported in conjunction with misfolded protein-
mediated pathogenesis in neurodegenerative disorders including early and late-stage Alzhei-
mer’s disease [20], Parkinson’s disease [21, 22], and multiple system atrophy [22]. More
recently, OXPHOS dysfunction has been identified within Purkinje neurons of a knock-in
ATXN1[154Q] SCA1 mouse model [23]; where treatment with an antioxidant ameliorated the
OXPHOS deficits [23].
In this study, we characterize OXPHOS dysfunction in a transgenic Purkinje-cell specific
model of SCA1, the B05 mouse. B05 mice selectively overexpress the physiologically relevant
ATXN1 mutant, ATNX1[82Q], in Purkinje neurons [24]. The mice develop an ataxic pheno-
type at 12 weeks of age, accompanied by accumulation of nuclear ATXN1[82Q] aggregates
and eventual Purkinje degeneration [24]. Pathogenesis does not spread outside of the cerebel-
lum; brainstem and spinal cord nuclei are spared, and mice are otherwise healthy. This model
allows us to determine the consequence of Purkinje cell expression of polyQ expanded-
ATXN1 on cerebellar OXPHOS in a transgenic model of SCA1.
We report here that OXPHOS complex I deficits are detectable in cerebellar preparations of
B05 mice using genetic, biochemical and physiological means. Specifically, adult B05 cerebel-
lum display upregulation of complex I genes, disassembly of complex I macromolecules and
reduced complex I respiration. Moreover, we hypothesized that bypassing complex I via exog-
enous treatment of the complex II electron donor, succinic acid [25–27], may have therapeutic
effects in the B05 mouse through the restoration of OXPHOS. Succinic acid, a Krebs cycle
metabolite, oxidizes to fumarate via complex II, succinate dehydrogenase [28–30]. In the pres-
ent study, we confirm that succinic acid in the cage drinking water elevates endogenous cere-
bellar succinate levels. Furthermore, treatment of symptomatic adult B05 mice for four weeks
improves cerebellar OXPHOS respiration, prevents Purkinje cell atrophy and mitigates ataxia.
These findings suggest augmenting mitochondrial activity, through succinic acid treatment,
may assist vulnerable neurons in defending against the prolonged internal assault of abnor-
mally stabilized aggregation-prone proteins.
Materials and methods
Mice and succinic acid treatment
SCA1 B05 and A02 transgenic mice on an FVB/nJ background strain were gifts from Dr.
Harry Orr (University of Minnesota). B05+/- mice express the ATXN1[82Q] transgene and
Succinic acid mitigates mitochondrial dysfunction, neurodegeneration and ataxia in SCA1 mice
PLOS ONE | https://doi.org/10.1371/journal.pone.0188425 December 6, 2017 2 / 20
A02+/- mice express the ATXN1[30Q] transgene, both under the control of the Purkinge cell-
specific promoter Pcp2/L7 [24, 31]. Wild type FVB/nJ mice were purchased from Jackson Lab-
oratory (Bar Harbor, ME, 001800). Transgenic lines were bred to homozygosity (B05+/+ and
A02+/+, referred to here as B05 and A02 for simplicity) and maintained along with wild type
mice at the Skidmore College mouse facility in strict accordance with the recommendations
established for the care and use of laboratory animals by the National Institute of Health and
approved by the Skidmore College Institutional Care and Use Committee (IACUC) (NIH Pub-
lications No. 8023, revised 1978). Transgene integration was verified in each generation by
PCR. Mice were fed chow ad libitum. Cage drinking water was replaced with 0.75 mg/mL suc-
cinic acid in treated mice and administered ad libitum beginning at age four months. Water
and treatment intake was measured daily. Cohort sizes of 8–14 mice per genotype were used
for neuropathology, behavioral assays, metabolic assays and circadian rhythm assays. Cohort
sizes of 3–4 mice per genotype were used for RNAseq, complex assembly analysis and oxygen
respiration. Mice were euthanized by displacement of the cage air with 10–30% compressed
carbon dioxide gas per minute. All animal protocols in this study were approved by the Skid-
more College IACUC.
RNA sequencing (RNA-Seq)
Gene expression profiling was conducted as recently published [32] on B05+/- and wild type
FVB cerebellar RNA at 5, 12 and 28 weeks of age. The chosen ages represent mild, moderate
and severe ataxia [33] in heterozygotes. Three biological replicates were run per genotype. For
the purpose of this study, statistically significant (P < 0.05) upregulation and downregulation
of nuclear OXPHOS complex genes in B05+/- compared to FVB were analyzed from the data
set provided by the Orr lab (University of Minnesota).
OXPHOS complex assembly western blot
To detect OXPHOS complex assembly, wild type untreated, B05 untreated and B05 treated
whole cerebellar homogenates were prepared in lysis buffer [0.25 M Tris-HCl, pH 7.5 con-
taining 1X protease inhibitors (Roche Biochemicals, Indianapolis, IN) and phosphatase
inhibitor cocktails 2 and 3 (Sigma, St. Louis, MO)]. Samples were combined with 1X
Laemmli reducing buffer at room temperature. 20 μg of unboiled samples were resolved in
triplicate by SDS-PAGE, transferred to nitrocellulose membranes and blotted with an assem-
bly-dependent total OXPHOS rodent antibody cocktail (AbCam ab110413, Cambridge MA).
Bands were visualized on a C-DiGit Western Blot Scanner (Licor Biosciences, Lincoln, NE)
and quantified using Image Studio densitometry software (Licor). CI, CII, CIII and CV band
densities were averaged and normalized to the average CIV band density. Data is expressed
as normalized means ± SEM.
Mitochondrial respiration
Mitochondrial respiration experiments were adapted from Kuznetsov, et al. [34]; our method-
ology for this study is described elsewhere [35]. Briefly, whole cerebella from treated and
untreated FVB and B05 mice were quickly extracted from CO2-asphyxiated wild type and B05
mice (treated and untreated) under IACUC guidelines and prepared in homogenate buffer
(0.25 M sucrose, 0.5 mM EDTA, 50 mM Tris-HCl, pH 7.4), and added to the calibrated respi-
rometer set to 30˚C (Oxytherm System, Hansatech Instruments, UK). Tissue plasma mem-
branes were permeabilized in the chamber with digitonin (15 μg/mL). Oxygen consumption
was recorded in response to the sequential addition of glutamate/malate (Complex I substrate,
10 mM and 5 mM, respectively), ADP (1 mM), rotenone (Complex I inhibitor, 0.5 μM),
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succinic acid (Complex II substrate, 10 mM), antimycin A (Complex III inhibitor, 5 μM),
TMPD/ascorbate (Electron donor, 0.5 mM and 2 mM, respectively) and cytochrome C
(10 μM). Percent of total respiration following activator and inhibitor addition was calculated
by normalizing the average oxygen consumption values by cerebellar wet weight and compar-
ing it to the corresponding normalized intra-assay response to TMPD/ascorbate. Three biolog-
ical replicates per genotype and treatment were averaged ± SEM.
HPLC
HPLC respiration experiments were adapted from Ergo¨nu¨l and Nergiz [36]; our adapted
methodology for this study is described in detail elsewhere [35]. In brief, PBS-washed cerebel-
lar, cortical, liver and kidney tissue from treated and untreated FVB and B05 mice were finely
minced in a chilled dounce homogenizer in 75:25 water: methanol, by volume. Following cen-
trifugation at 1300 x g at 4˚C for 30 minutes, supernatants were filtered through regenerated
cellulose with a 10 kDa nominal molecular weight limit. Samples and known succinic acid
standards were diluted in degassed 1 mM acetate buffer (pH = 5) mobile phase and run by
HPLC through a Shodex KC-811 ion exclusion chromatography column with a length 30
cm and a particle size of 7 μm. Mobile phase velocity was set to 0.8 mL/minute and a UV-vis
detector was set to 224 nm. Peak areas of standards were used to obtain a standard calibration
curve. Succinic acid concentrations of samples were determined from the calibration curve,
multiplied by the sample volume and divided by the original sample mass. All standards and
samples were analyzed in triplicate.
Neuropathology
Whole cerebellar tissue was quickly harvested from CO2-asphyxiated FVB and B05 mice
(treated and untreated) under IACUC guidelines, and immediately fixed in ice cold 4% para-
formaldehyde overnight. Following fixation, tissue was sunk in 30% cold sucrose over three
days, embedded in O.C.T. Compound (Fisher Healthcare) and cut into 50 μm sagittal sections
on a sledge microtome (ERMA ESM-100L, Tokyo, Japan). Following an established protocol
[37], epitopes were unmasked by boiling three times for 15 seconds each in 0.01 M urea,
blocked for 1 hour in 2% normal donkey serum and 0.3% Triton X-100 in 1X PBS, and incu-
bated for 48 hours at 4˚C in blocking solution containing goat calbindin antibody (SC-7691,
Santa Cruz) at 1:500. Sections were washed four times in 1X PBS, and incubated for 48 hours
at 4˚C in blocking solution containing 1:500 Alexa 488-donkey anti-goat (ThermoFisher Sci-
entific). Sections were washed and mounted onto microscope slides with glycerol-gelatin con-
taining 4 mg/mL n-propyl gallate (Sigma) and imaged on an Olympus Fluoview 1200 upright
microscope as previously described [38].
Confocal images of cerebellar primary fissures were captured from 20 μm z-stacks at 20X
objective. Molecular layer thickness was measured in Image J by scorers that were blinded to
the genotype and treatment conditions. Two designated 200 μm stretches of primary fissure
along the Purkinje layer were identified in each image, and three random measurements were
made within each 200 μm stretch from the proximal end of the Purkinje dendritic arbor at the
base of the soma to the distal end of the dendritic arbor [35, 37]. Six measurements from three
cerebellar sections per animal were averaged and expressed as the mean ± SEM.
To analyze Purkinje cell counts, cerebellar sections from A02 transgenic mice and B05
transgenic mice (treated and untreated) were prepared as described above, incubated in 11NQ
anti-ATXN1 antibody (1:2000) [9], and detected with 1:500 Alexa 594-goat anti-rabbit second-
ary antibody (ThermoFisher Scientific). Following confocal imaging of primary fissures, two
designated 200 μm stretches along the Purkinje layer were identified, and the number of
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ATXN1-positive nuclei within each stretch were counted manually [35] by blinded scorers. Six
measurements from three cerebellar sections per animal were averaged and expressed as the
mean number of soma ± SEM.
Footprint testing
Gait assessment was measured by labeling hind feet of mice with blue or red non-toxic
water-based paint, placing subjects on a paper-lined runway and allowing them to walk
towards a goal box, as described in detail previously [33, 35]. Successful trials were defined
as a minimum of five sequential footprints in which the subject walked towards the goal
box without turning or stopping [35]. Step length, gait width, alternation coefficient, and
linear movement were assessed from the footprints as described previously [33] by blinded
scorers. Measurements from subjects within the same genotype and treatment cohorts were
average and expressed ± SEM.
Balance beam testing
Motor deficits and ataxia were assessed by the balance beam test as described previously [33,
35]. Specifically, mice were tested on a trial beam (12mm square) for 3 trials per day for three
days. On the subsequent testing day, mice were run across 6 beams which alternated between
square and round, and ranged from 28 mm to 6 mm, sequentially declining in thickness and
radius. Mice were assayed on testing day (day 4) for the number of footslips made by their left
hindfoot as they crossed beam three successfully, and by the number of successful attempts
that it took for them to cross each beam. Videotaped footage was evaluated by blinded scorers
to score the number of footslips and successful trials. Measurements from subjects within the
same genotype and treatment cohorts were average and expressed ± SEM.
Accelerating rotarod testing
Ataxia was further assessed by the accelerating rotarod protocol in which rod speed was gradu-
ally accelerated between 4 and 40 rpm over a 5-minute period, then maintained at a constant
acceleration for up to five additional minutes [33, 35] (Rotallion Rotarod; PPP&G, Saint
Paul, MN). Latency to fall was recorded over four trials per day for four consecutive days. Mea-
surements from subjects within the same genotype and treatment cohorts were average and
expressed ± SEM.
Energy expenditure
Energy expenditure was assessed in A02 mice using metabolic cages (OxyMax, Columbus
Instruments, Columbus, OH) equipped with O2 and CO2 analyzers according to the manufac-
turer’s instructions [39]. Following an 8-hour acclimatization period, energy expenditure was
assessed continuously during a 24-hour dark-light period with ad libitum access to food and
treated (eight females and seven males, age 300 +/- 16 days) or un-treated water (five females
and eight males, age 297 +/- 14 days). The volume of oxygen consumed (VO2), volume of car-
bon dioxide produced (VCO2), energy expenditure (HEAT) and the respiratory exchange
ratio (RER), the ratio of CO2 to O2, were recorded over time. Mean data points were plotted
over time and t-tests were used to determine significant differences of each measure between
treated and untreated male or female cohorts.
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Circadian rhythm analysis
Circadian rhythms were analyzed in mice as previously described for rats [40]. Briefly, A02
mice were housed in individual plastic cages equipped with a Nalgene running wheel (Mini
Mitter, Bend, OR) and with ad libitum access to food and treated (eight females and seven
males, age 300 +/- 16 days) or un-treated water (five females and eight males, age 297 +/- 14
days). Running wheel activity was assayed for ten days under a 12:12 light dark cycle
(12:12LD) after four days of acclimation to the running wheel cages, followed by ten days in
constant dim red light (DD). Monochromatic red light was produced using Kodak filter num-
ber one, and measured less than one lux at the top of each cage. Running wheel activity data
was collected in 10-minute bins using VitalView software (Mini Mitter) and analyzed using
ActiView software (Mini Mitter). Mean activity level was assayed in 12:12LD (XLD), the light
phase of the LD cycle (XL), the dark phase of the LD cycle (XD) and in constant dark (XDD).
Peak time of activity in 12:12LD (PHLD) and the free-running circadian period in DD
(TAUDD) were also analyzed. To prevent circadian disruptions in the analysis, routine proce-
dures occurred at random times during the light period of the LD cycle.
Statistics
Statistical analyses are indicated in figure legends. In general, comparisons of statistical signifi-
cance of difference by a single effect were evaluated by t-test. Comparisons of statistical signifi-
cance of difference by multiple effects were evaluated by one- or two-way ANOVA and the
Tukey post hoc test. T-tests and ANOVAs were conducted in GraphPad Prism. Running
wheel cage data was analyzed in SAS using the GLM procedure. Data, where indicated, are rep-
resented as mean ± SEM.
Results and discussion
Oxidative phosphorylation complexes are dysfunctional in B05 mice
cerebellum
Oxidative phosphorylation complex dysfunction was analyzed in B05 mouse cerebellum via
three different measures. First, RNAseq analysis was performed on B05 and wild type cerebella
prior to behavioral and neurological deficits of SCA1 (5 weeks of age) [24, 41], early stage
SCA1 (12 weeks) and advanced stage SCA1 (28 weeks) [24, 32](Table 1). OXPHOS complex
genes that were significantly (P< 0.01) downregulated (top) or upregulated (bottom) in B05
compared to age-matched wild type are noted in Table 1. The complex 4 gene, Cox6b2, which
is highly expressed in Purkinje cells [42] and the ATPase gene, Lhpp, were downregulated in
B05 cerebellum compared to control cerebellum at 5 weeks of age. Both genes remained down-
regulated at 12 weeks of age. In contrast, no OXPHOS genes were upregulated in B05 at 5
weeks. At 12 weeks of age, the complex I genes Ndufb2 and Ndufb3, complex II genes Sdhc
and Sdhd, complex III gene Uqcrh, complex 4 genes Cox5a, Cox6a1, and Cox4i1 and ATPase
gene Atp5g3 were downregulated. At 28 weeks of age, OXPHOS downregulation was not
detected. Upregulation of complex I genes Ndufa11, Ndufb5, Ndufs5 and Ndufv2, complex III
gene Uqcrq, complex IV genes Cox7a21 and Cox7b and ATPase gene Atp5j2 were upregulated
at 12 weeks. Upregulated expression of Ndufa11, Uqcrq, Cox7a21 and Atp5j2 persisted
through 28 weeks. Additionally, at 28 weeks, complex I genes Ndufa11, Ndufa6, Ndufa7,
Ndufb10, Ndufb7, Ndufb8, Ndufb9 and Ndufs8, complex II gene Sdhc, and complex III gene
Uqcr11 were upregulated. The greatest downward fold change in B05 compared to wild type
was in Cox6b2 (log 2-fold change of 1.77038 and 1.27923 at 5 weeks and 12 weeks, respec-
tively) and the greatest upward fold change was in Ndufs5 (log 2 fold change of -1.67463).
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Next, we analyzed OXPHOS complex protein assembly by western blotting using an assem-
bly specific antibody cocktail (Fig 1A). 20-week old B05 and wild type cerebellar lysates were
prepared in SDS sample buffer, but were not boiled to preserve complex assembly, as per man-
ufacturer’s instructions. As a result, we did not include a typical loading control but instead
relied on the reproducibility of the complex IV subunit across samples as our normalization
factor. Compared to complex IV which showed no change in assembly, the complex I subunit
levels were significantly reduced indicating decreased complex I assembly (Fig 1B). No signifi-
cant reduction was seen in complex II, III or V (ATPase).
Finally, we examined respiratory activity of adult B05 cerebellum compared to wildtype cer-
ebellum using permeabilized whole tissue respirometry (Fig 1C). The benefit of whole tissue
versus mitochondrial preparations is to prevent bias by including unhealthy or damaged mito-
chondria in the analysis. Our results show a significant reduction of complex I-driven respira-
tion (Glu+Mal+ADP) in B05 cerebellum compared to wild type cerebellum suggestive of a
functional deficit in complex I (Fig 1C). To confirm this, the complex I inhibitor, rotenone,
was applied (Glu + Mal + ADP + Rotenone) and the difference in total respiration between
B05 and wild type was abolished, further suggesting diminished complex I activity in SCA1
(Fig 1C). Taken together, the above transcriptional, biochemical and physiological data indi-
cate complex I dysfunction occurs during SCA1.
Table 1. RNAseq analysis of OXPHOS complex genes in B05 cerebellar tissue versus wild type tissue.
Downregulation of OXPHOS complex genes in B05
(log 2 fold change)
Complex I Complex II Complex III Complex IV ATPase
vs Wt-5 wks *Cox6b2 (1.77038) Lhpp (0.641673)
vs Wt-12 wks Ndufb2 (0.634449) Sdhc (0.515247) Uqcrh (0.335416) Cox5a (0.404022) Atp5g3 (0.342982)
Ndufb3 (0.457995) Sdhd (0.477251) Cox6a1 (0.514417) Lhpp (0.780756)
*Cox6b2 (1.27923)
Cox4i1 (0.368788)
vs Wt-28 wks
Upregulation of OXPHOS complex genes in B05
(log 2 fold change)
Complex I Complex II Complex III Complex IV ATPase
vs Wt-5 wks
vs Wt-12 wks Ndufa11 (-0.349446) Uqcrq (-0.416653) Cox7a2l (-0.328557) Atp5j2 (-0.516911)
Ndufb5 (-0.356859) Cox7b (-0.326646)
Ndufs5 (-1.67463)
Ndufv2 (-0.552158)
vs Wt-28 wks Ndufa11 (-0.509067) Sdhc (-0.498714) Uqcr11 (-0.454752) Cox7a2l (-0.583099) Atp5j2 (-0.493386)
Ndufa6 (-0.507489) Uqcrq (-0.650516)
Ndufa7 (-0.480316)
Ndufb10 (-0.4287)
Ndufb7 (-0.502352)
Ndufb8 (-0.599094)
Ndufb9 (-0.434831)
Ndufs8 (-0.450487)
Top table lists genes upregulated (P<0.01) in B05 compared to wild type at 5, 12 and 28 weeks. Bottom table lists genes downregulated (P<0.01) in B05
compared to wild type at 12 and 28 weeks. Complex genes were not downregulated at 5 weeks.
*Indicates Purkinje-cell enriched genes [42].
https://doi.org/10.1371/journal.pone.0188425.t001
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Ad libitum succinic acid as a treatment strategy for B05 mice
As a strategy to overcome potential OXPHOS complex I dysfunction, we hypothesized that
bypassing complex I in the electron-transfer chain may have therapeutic potential. Succinic
acid, a Krebs cycle-generated metabolite, donates electrons directly into complex II and thus
could be used to bypass complex I [25–27, 30] (Fig 2A). Additionally, succinic acid is inexpen-
sive, endogenous and FDA-approved making it an attractive therapeutic [43–47]. A concentra-
tion of 0.75 mg/mL of succinic acid dissolved in the cage drinking water and administered ad
libitum was chosen based on preliminary dose-response data. We first tested whether mice
will drink 0.75 mg/mL succinic acid by weighing water bottles of treated and untreated mice
daily for 16 days (Fig 2B). Volume of intake did not change drastically over the 16-day period.
Minor variability was observed in both treatment groups likely due to the timing of the mea-
surement on that day. Overall, there was a significant decrease of about 1 mL per day in the
intake volume of treated versus untreated water (Fig 2C). The intake volume per treated
mouse was consistent however, resulting in an intake dosage of approximately 4 mg of succinic
acid per mouse per day.
Fig 1. OXPHOS complex I dysfunction in adult B05 cerebellum. (A) OXPHOS complex assembly in B05 (lanes 1–3) and wild type (lanes
4–6) cerebellum by Western blot using an assembly-specific OXPHOS antibody cocktail. (B) Quantification of western blot data in (B). CI, CII,
CIII and CV bands are each normalized to CIV. Data is in triplicate. Error bars show means ± SEM. T-test, * P < 0.05. (C) Mitochondrial
respiration analysis of B05 and wild type cerebellum in the presence of ADP or rotenone. Data is shown as the percent maximal respiration which
was calculated in the presence of TMPD/Ascorbate. Samples were run in triplicate. Error bars show means ± SEM. T-test, * P< 0.05.
https://doi.org/10.1371/journal.pone.0188425.g001
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We next sought to determine if ad libitum succinic acid dissolved in the cage drinking
water would bypass the blood brain barrier. To address this, we adapted a protocol for measur-
ing succinic acid concentrations in olive fruit strains to our cerebellar samples [47]. A biologi-
cal vehicle was spiked with known succinic acid concentrations and used to develop a
standard curve by HPLC (Fig 2D). PBS-washed cerebellar tissue from vehicle-treated and suc-
cinic acid-treated mice were detected by the HPLC assay. Succinic acid-treated cerebellar tis-
sue featured approximately 133% more succinic acid than endogenous levels in the untreated
cerebellar tissue (Fig 2E).
Having established that succinic acid can be effectively administered via cage water bottles
and that it crosses the blood brain barrier, we designed the following protocol scheme to
Fig 2. SA as a treatment strategy for B05 mice. (A) Schematic (drawn in ChemDraw) showing mitochondrial inner membrane (IMM) OXPHOS
complexes, flow of protons (H+), redox and phosphorylation reactions, and the flow of electrons (thick black lines). OMM = outer mitochondrial
membrane. (B) Volume of water measured daily in untreated and succinic acid treated mice. (C) Average water intake over a two-week period in treated
(SA) (mean = 5.415 ± 1.069 mL) and untreated (6.463 ± 1.058 mL) mice. Error bars represent means ± SEM. T-test, ****P < 0.0001. (D) Standard curve
of succinic acid by HPLC. Slope = 0.01939 ± 0.0007448, R2 = 0.9956. (E) succinic acid concentrations in cerebellar tissue detected in untreated and
4-week treated wild type mice. Error bars represent means ± SEM. T-test, P < 0.0001. (F) Schema of treatment plan. Symptom onset begins
approximately 5 weeks after birth. We began treatment of 0.75 mg/mL succinic acid beginning at 4 months of age and continued for four weeks. Subjects
were behaviorally tested during weeks 2 (footprint analysis), 3 (beam analysis) and 4 (accelerating rotarod). Following treatment, 5 month-old mice were
sacrificed and cerebellar tissue was harvested for oxygen respiration analysis and neuropathology.
https://doi.org/10.1371/journal.pone.0188425.g002
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administer succinic acid to B05 mice (Fig 2F). B05 mice first exhibit neuropathological and
behavioral deficits at 12 weeks of age [24]. In order to allow these deficits to develop, we began
treatment at 4 months of age continuously for four weeks. During week 2 of treatment, ani-
mals were analyzed for gait and balance via a footprint assay; during week 3 of treatment, ani-
mals were analyzed for motor learning via balance beam analysis; and during the final week of
treatment, animals were analyzed for balance and motor learning via the accelerating rotarod
paradigm. Following treatment, at 5 months of age, mice were sacrificed and their cerebella
were extracted for immunostaining and mitochondrial respiration.
Succinic acid treatment augments OXPHOX complex function in B05
mice cerebellum
The effects of succinic acid treatment on oxygen consumption was assessed by respirometry.
The significant reduction in complex I-driven respiration in the B05 cerebellum compared to
wild type cerebellum (Fig 1C) persisted in succinic acid-treated B05 cerebellar tissue (Fig 3A
and 3B). Furthermore, inhibition of complex I with rotenone had no effect on oxygen con-
sumption (Fig 3B). With selective activation of complex II-driven respiration (Glu+Mal, ADP,
Rotenone, and succinic acid), no significant differences were found between groups (Fig 3C),
suggesting along with the protein assembly data (Fig 1A and 1B), that complex II and further
downstream complexes, appear to be relatively intact. Moreover, succinic acid treatment did
not disrupt complex II or downstream oxygen consumption. However, interrogation of com-
plex III activity with the Qi site-specific complex III-inhibitor antimycin A [48] shows that
B05 cerebellar mitochondria were less affected by complex III blockade (Fig 3D). Importantly,
this effect is rectified with succinic acid treatment (Fig 3D). Finally, exploration of mitochon-
drial membrane integrity revealed that B05 cerebellar mitochondria responded significantly to
cytochrome C addition (Fig 3E). This finding is suggestive of either low cytochrome C pools
within B05 cerebellar tissue, or that SCA1 pathogenesis is initiating damage to the mitochon-
drial membrane [34]. Both potential causes will require further investigation. Importantly, the
effect of any damage is reversed with succinic acid treatment (Fig 3E).
Succinic acid treatment ameliorates molecular layer and Purkinje cell
layer degeneration in B05 mice cerebellum
Fixed, frozen sagittal sections of cerebellar tissue were cut to 50 μm thickness and stained for
calbindin, a marker of Purkinje cell soma and dendrites or 11NQ, an ataxin-1 antibody which
preferentially stains Purkinje cell nuclei in SCA1 transgenic mouse models. Images of sagittal
sections surrounding the primary fissure were captured by confocal microscopy. Purkinje cell
dendritic length was measured in calbindin-stained tissue from the soma to its endpoint
towards the primary fissure. Representative images for untreated (vehicle-treated) wild type,
untreated B05 and treated B05 are shown in Fig 4A. Average molecular layer thickness, a mea-
sure of Purkinje cell dendrite extension, is graphed in Fig 4B. No difference is seen in treated
or untreated wild type. A significant reduction in molecular layer length is seen in untreated
B05. And a significant increase in molecular layer length is detected with ad libitum treatment
of succinic acid (Fig 4B).
Purkinje cell nuclei were counted in 11NQ-stained slices from an untreated transgenic con-
trol mouse (A02, which expresses ATXN1[30Q] diffusely in Purkinje cell nuclei but does not
exhibit SCA1 neuropathological or behavioral deficits), untreated B05 (which expresses aggre-
gated ATXN1[82Q] in Purkinje cell nuclei) and treated B05. Representative images are shown
in Fig 4C, and average number of Purkinje nuclei are graphed in Fig 4D. There was no statisti-
cal difference in the number of 11NQ-positive Purkinje cells between treated and untreated
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wild type cerebellum (Fig 4D). As with the molecular layer thickness measure, Purkinje cell
nuclei were significantly reduced in untreated B05 but that reduction was prevented with ad
libitum treatment of succinic acid (Fig 4C and 4D).
Succinic acid treatment improves the cerebellar ataxia phenotype in B05
mice
Gait was measured during the second week of the four-week ad libitum treatment of succinic
acid using the footprint assay. The footprint assay is a simple paradigm in which hind feet are
painted with blue (left foot) or red (right foot) paint and mice are allowed to walk on a paper-
lined runway towards a goal box. Each mouse performed the assay successfully one time.
Gait width, step length, linear movement and alternation coefficient was analyzed [33, 35].
We did not detect a difference in gait width or linear movement due to genotype or treatment
Fig 3. 1 month SA treatment restores OXPHOS complex function in adult B05 mice. (A-E) Oxygen respiration response of wild type
untreated, B05 untreated and B05 treated mice cerebellar tissue to the addition of (A) 1 mM ADP, (B) 0.5 μM rotenone, (C) 10 mM succinic
acid, (D) 5 μM antimycin A, and (E) 10 μM cytochrome C. Responses are the percent of maximal respiration as measured by the oxygen
respiration response to the simultaneous addition of 0.5 mM TMPD and 2 mM ascorbate. Error bars represent means ± SEM. One-way
ANOVA with Tukey’s post-hoc test, * P < 0.05, NS = non-significant.
https://doi.org/10.1371/journal.pone.0188425.g003
Succinic acid mitigates mitochondrial dysfunction, neurodegeneration and ataxia in SCA1 mice
PLOS ONE | https://doi.org/10.1371/journal.pone.0188425 December 6, 2017 11 / 20
condition. The lack of significant results is likely due to a combination of the insensitivity of
the assay and the reduced time of treatment. When calculating step length, the untreated wild
type mouse did not show a significant increase in step length compared to the untreated or
treated B05 mice. However, both the untreated and treated B05 mouse showed significantly
reduced step length compared to the treated wild type mouse (Fig 5A). Alternation co-effi-
cient, a measure of shuffle, was not affected in wild type mice by treatment. A trend of
increased shuffle was seen between the untreated B05 mouse and wild type mice, although the
increase was not significant. However, a statistically significant reduction in shuffle was found
in B05 mice due to treatment (p< 0.05) (Fig 5B).
Footslips and beam cross attempts were assessed during the third week of treatment via the
balance beam test [33, 35] (Fig 5C–5E). B05 mice made a significantly greater number of foot-
slips on beam 3 than wild type mice, and succinic acid treatment did not alter the number of
footslips (Fig 5C). Fig 5D shows the number of attempts made to successfully cross the square
beams (beams 1, 3 and 5). A trend towards an increased number of attempts is seen in
untreated B05 compared to untreated wild type mice. However, we found a significant
decrease in the number of attempts to cross each of the three square beams by treated B05
mice compared to untreated B05 mice. (Fig 5D). Fig 5E shows the number of attempts made
to successfully cross the round beams (beams 2, 4 and 6). A significant increase in the number
of attempts is seen in untreated B05 compared to untreated wild type (Fig 5E). Unlike with the
square beams, succinic acid treatment did not decrease the number of attempts that B05 mice
took to successfully cross the round beams (Fig 5E). The balance beam data as a whole suggests
that succinic acid treatment may improve cerebellar motor behavior in the SCA1 B05 mouse.
Improvement to the ataxia phenotype was directly assessed during the fourth week of treat-
ment via the accelerated rotarod. Fig 5F shows the data from the final trial and Fig 5G shows
the results of all 16 trials over four days for untreated and treated wild type mice, and untreated
Fig 4. 1 month SA treatment slows Purkinje neuron degeneration in adult B05 mice. (A) Representative calbindin-stained
cerebellar primary fissure images from untreated wild type, untreated B05 and treated B05 mice. (B) Molecular layer thickness,
a measure of calbindin-positive Purkinje dendritic length, in treated and untreated wild type and B05 cerebellum. (C)
Representative ATXN1-stained cerebellar primary fissure images from untreated control transgenic (A02), untreated B05 and
treated B05 mice. (D) Purkinje nuclei counts in treated and untreated A02 and B05 cerebellum. Error bars represent
means ± SEM. Two-way ANOVA,* P < 0.05, ** P < 0.01.
https://doi.org/10.1371/journal.pone.0188425.g004
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and treated B05 mice. Untreated wild type mice showed gradual improvement over the sixteen
trials, and improved their latency-to-fall time by one minute at trial 16 (Fig 5F and 5G). Sur-
prisingly, treated wild type mice performed even better than untreated wild type mice showing
a significant improvement from untreated mice during trials 9, 10, 11 and 13, but not the final
trial (Fig 5F and 5G). In contrast, untreated B05 mice were unable to remain on the rotarod
for more than a couple of seconds on trial 1. While they also showed improvement over the 16
trials, their performance during the final trial remained under 50 seconds (Fig 5F and 5G).
They performed significantly worse than untreated wild type mice during each of the 16 trials.
Treated B05 mice performed equally to the untreated B05 mice in early trials, yet showed sig-
nificant improvement, when compared to untreated B05 controls, in trials other than the first,
Fig 5. 1 month SA treatment improves cerebellar behavior in adult B05 mice. (A) Step-length, measured by the footprint runway assay during week 2
of treatment, in wild type (black bars) and B05 (gray bars) untreated (solid bars) and treated (dashed bars) mice. (B) Alternation coefficient, measured by
the footprint runway assay during week 2 of treatment. Calculated values reflect the extent of shuffle gait. (C) Number of hind left foot slips during
successful crossing of beam 3 on testing day during week three of treatment. (D) Number of trials needed for a successful cross of square beams 1, 3 and
5 on testing day during week 3 of treatment. (E) Number of trials needed for a successful cross of round beams 2, 4 and 6 on testing day during week 3 of
treatment. (F) Latency to fall during trial 16 of the accelerating rotarod test during week 4 of treatment. (G) Latency to fall during all trials of the accelerating
rotarod test during week 4 of treatment. Error bars represent means ± SEM. Two-way ANOVA, * P < 0.05, ** P < 0.01.
https://doi.org/10.1371/journal.pone.0188425.g005
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second and fourth. Furthermore, by the final trial, treated B05 mice performed equally to wild
type mice (Fig 5F).
Our behavioral tests, administered during the final three weeks of the four-week treatment
period, show that succinic acid improves cerebellar behavior in B05 mice. Improvement in
shuffle, but not in step length, was seen during week 2 of treatment. Improvement in perfor-
mance on the tested beams (square) were seen during week 3 of treatment. No improvement
in footslips was shown during week 3 of treatment. During week 4 of treatment, latency-to-fall
during the accelerated rotarod training paradigm improved starkly in treated B05 mice, which
began trial 1 at the same level as dysfunction as the untreated mice. In concert, our behavioral
data strongly favors a model by which succinic acid ad libitum treatment ameliorates behav-
ioral decline in B05 mice caused by Purkinje cell degeneration.
Chronic succinic acid treatment in adult mice does not perturb overall
metabolism
Given the ubiquitous nature of succinic acid in the body and the impact that increasing suc-
cinic acid levels can have on metabolism and physiology [49–54], we further tested the effects
of ad libitum succinic acid treatment in adult wild type mice apart from its function on Pur-
kinje cells. First, we measured the concentration of succinic acid delivered to the cortex,
liver and kidneys in response to cage water treatment for 1 week or 5 weeks (Fig 6A). A dose
response was found in each of the three regions, with the highest concentrations of succinic
acid found in the liver (Fig 6A). Next, we turned to a chronic ( 4 months) ad libitum treat-
ment model to investigate potential side effects of treatment. We analyzed cerebellar OXPHOS
complex assembly and detected reduced assembly of complexes I, II and III in chronically
treated wild type mice. Complex IV and V assembly were not affected (Fig 6B). Next, we mea-
sured the weight of adult wild type chronically treated and untreated mice. No significant
difference in weight of adult males or females due to chronic treatment was found (Fig 6C).
Average water intake over a 24-hour period was not different between chronically treated and
untreated mice (Fig 6D).
To measure potential changes to overall metabolism due to chronic treatment, chronically
treated and untreated A02 mice were placed into metabolic cages with free access to food and
either treated or untreated water. Mice were allowed 8 hours of acclimation time before begin-
ning the testing period in 12-hour dark and 12-hour light cycles. Four variables were recorded
3–4 times per hour over a 15.75-hour period that included 7 hours of dark time and 8.45 hours
of light: oxygen consumption (VO2), carbon dioxide production (VCO2), respiratory exchange
ratio (RER) and energy expenditure (HEAT) (Fig 6E–6H). VO2 (Fig 6E), VCO2 (Fig 6F), RER
(Fig 6I) or HEAT (Fig 6H) in untreated and treated male and female mice are shown over
time. Repeated measures two-way ANOVA was used to determine the effects of treatment and
sex on the above variables. No statistical difference due to sex or treatment was found in VO2,
VCO2 or RER. A main effect (p< 0.001) was found in energy expenditure. Tukey’s post-hoc
analysis revealed an interaction of sex x time among treated subjects (p< 0.05); Fig 6H shows
increased energy expenditure measures in female treated mice compared to male treated mice.
Further analysis of the energy expenditure results was investigated with multiple comparisons
t-test analysis to determine the effects of treatment or sex at each time point. A single time
point (at 3 hrs:54 mins, dark cycle) showed a statistically significant effect of treatment on
energy expenditure in female mice (P< 0.05). A sex effect on energy expenditure was found
in the untreated subjects that persisted from 1 hr:48 mins to 5hrs:6 mins (first 20 minutes in
light, remaining 3 hours in dark) (P< 0.05 or lower at each time point). A more pronounced
sex effect on energy expenditure was found in the treated males versus females beginning at 1
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hr:48 mins and occurred discontinuously through the remainder of the recorded period (first
20 minutes in light, followed by 12 hours in dark, followed by 40 minutes in light) (P< 0.05 or
lower).
To further test the metabolic effects of chronic succinic acid treatment, we tested circadian
free-running activity. Succinate treatment had no significant effect on the free-running circa-
dian period in DD or the time of peak activity 12:12LD (Table 2) indicating that the circadian
timing of activity and the period of the circadian pacemaker driving the activity rhythm in DD
are not changed by the treatment. None of the measures of mean activity level in 12:12LD or
DD were significantly altered by succinate treatment (see Table 2). There were no significant
Fig 6. Chronic (> 4 months) SA treatment of adult mice does not alter overall metabolism. (A) HPLC analysis of cortex, liver and kidney from wild
type mice treated with 0.75 mg/mL succinic acid for 0, 1 or 5 weeks shows elevated levels in these regions. Error bars represent means ± SEM. (B)
Chronic treatment of adult mice does alter complex I, complex II and complex III assembly in cerebellar tissue of wild type mice as determined by western
blotting with an OXPHOS complex assembly-dependent antibody cocktail. Error bars represent means ± SEM. * P < 0.05. (C) Weight of chronically
treated male and female wild type mice is not significantly different from untreated. Error bars represent means ± SEM. NS = non-significant. (D) Water
intake during running wheel assay of chronically treated male and female wild type mice is not significantly different from untreated. Error bars represent
means ± SEM. NS = non-significant. (E-H) Metabolic cage testing of chronically treated male and female wild type mice and untreated male and female
wild type mice showing (E) oxygen consumption (VO2), (F) carbon dioxide production (VCO2), (G) respiratory exchange ratio (RER) and (H) energy
expenditure (HEAT). X-axes shows the time scale from 0:00 to 15:42 (hr:min) of recorded time. Black points indicate SEM. Statistical analyses are
described in the results.
https://doi.org/10.1371/journal.pone.0188425.g006
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interactions between succinate treatment and sex effects. Yet, mice treated with succinic acid
are consistently less active for all measures of activity (Table 2). Further analysis will be needed
to assess the effect of chronic treatment on Purkinje cells and cerebellar behavior.
Conclusions
Deficits in complex I of the mitochondrial electron transport chain, in particular, have
reported to affect and/or accompany neurodegeneration and toxicity in vulnerable neurons
[55, 56]. A decrease of complex I activity occurs with age, and is further pronounced in the
striatal and nigral neurons of Parkinson’s disease [21, 22]. Substantial down-regulation of
complex I subunit genes are found in Alzheimer’s disease [20]. Loss of frataxin function in
Friedrich’s ataxia results in accumulation of mitochondrial iron that selectively reduces com-
plex I activity [14, 19]. Additionally, several mutations in the nuclear-encoded subunits of
complex I are reported to cause Leigh syndrome [14, 15]. In the case of Friedrich’s ataxia and
Leigh syndrome, both juvenile fatal disorders, complex I deficiency disrupts cerebellar func-
tion as is evident by the common symptom of cerebellar ataxia [14, 15, 19]. Most recently,
complex I deficiency and other mitochondrial dysfunction was reported in a knock-in ATXN1
[154Q] mouse model [23].
Our present study investigates complex I function in the cerebellum of the B05 mouse
which selectively expresses the ATXN1[82Q] transgene. Advantages of this model include the
Purkinje neuron- specificity of transgene expression and the biological relevance of the 82Q-
length expanded polyglutamine tract [57, 58]. The impact of ubiquitous succinic acid delivery
specifically on cerebellar cells exposed to ATXN1[82Q] in our mouse model can be examined.
We found that succinic acid boosts cerebellar function in the B05 mouse following short-
term treatment. Succinic acid crosses the blood brain barrier and penetrates cerebellar tissue.
In whole cerebellar tissue, succinic acid bypasses dysfunctional complex I without disrupting
complex II or downstream oxygen consumption, restores complex III inhibition by antimycin
A, and prevents damage of outer mitochondrial membranes. Within Purkinje neurons, suc-
cinic acid diminishes Purkinje dendritic atrophy and averts loss of Purkinje soma. On a behav-
ioral level, succinic acid lessens the cerebellar ataxia phenotype.
Succinic acid is a low cost, readily available organic compound that has been reported to
bypass complex I and stimulate activity of complex II [25–27]. Inhibition of succinic acid by
Table 2. Chronic (> 4 months) SA treatment of adult mice does not alter overall activity.
Variable Control Treated
XLD 30.4 ± 3.2 26.2 ± 5.0
XL 14.8 ± 2.2 11.6 ± 2.8
XD 46.1 ± 6.0 40.8 ± 8.3
XDD 35.3 ± 4.2 24.6 ± 5.0
PHLD 23.4 ± 0.5 22.7 ± 0.6
TAUDD 23.65 ± 0.07 23.48 ± 0.11
Age 300 ± 15 297 ± 14
Data table shows mean +/-SEM activity levels (average wheel revolutions per ten minutes), circadian timing
of activity (hours) in LD and DD, and age (days). XLD = mean number of wheel turns in 12:12 LD per 10
minutes; XL = mean number of wheel turns in L during LD (per 10 minutes); xd = mean number of wheel
turns in D during LD; XDD = mean number of wheel turns during DD (per 10 minutes); TAUDD = period of
the circadian wheel-running rhythm during DD (in hours); PHLD = time of peak activity during LD. None of
the variables were significantly different between control and treated mice.
https://doi.org/10.1371/journal.pone.0188425.t002
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the reversible inhibitor malonate and the irreversible inhibitor nitropropionic acid causes neu-
rodegeneration in animal models [59–61]. In our mice model, it is an effective means of cir-
cumventing complex I dysfunction and ameliorating the effects of ATXN1[82Q]-driven
neurodegeneration in B05 Purkinje cells.
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